
Serum Institute of India is to produce 300 million dose of Sputnik V vaccine and its first batch is likely to be in September. Details emerged with the Russia’s sovereign wealth fund RDIF announcing, a collaboration with the vaccine maker to manufacture Sputnik V for the India market as well as to exports to several countries.
Russian Direct Investment Fund CEO Kirill Dmitriev said in a media briefing from Moscow that
"We have reached a partnership agreement with Serum Institute of India to manufacture Sputnik V”
CEO of Serum Institute of India (Pune based) Adar Poonawalla said “we hope to make millions of doses in the coming months with trial batches starting in September. With high efficacy and a good safety profile, it is critical that the Sputnik vaccine is accessible in full measure for people across India and the world.”
As part of the technical transfer process, SII has already received cell and vector samples from the Gamaleya Center. With their import approved by the Drug Controller General of India), the cultivation process has begun," statement from RDIF.
India will soon achieve the tag of leading producers of the hub for Sputnik V Vaccine. Dr. N K Arora, who heads the National Expert Group on Vaccine Administration, stated that the government will b e able to meet its December target.